Table S 4: P values (two-sided) within each treatment group for absolute changes of total symptom scores from baseline (day 1) to respective treatment days. Values are shown for the entire patient set (Modified Intention-To-Treat analysis set, n=84) and for the patient group with baseline Ct values lower than 20. Values shown in bold are statistically significant (p<0.05).

|  |  |  |  |
| --- | --- | --- | --- |
| **Total symptom score** | all patients (n=84) |  | patients with baseline Ct values lower than 20 (n=25) |
|  | Azelastine 0.1% | Azelastine 0.02% | Placebo | Azelastine 0.1% | Azelastine 0.02% | Placebo |
| Day 2 | 0.0521 | 0.3835 | **0.0052** | 0.7734 | 0.1719 | 0.3750 |
| Day 3 | **0.0448** | 0.6171 | **0.0033** | 0.5859 | 0.7031 | 0.3125 |
| Day 4 | **0.0095** | 0.1872 | **0.0125** | 0.6172 | 0.4766 | 0.1250 |
| Day 5 | **0.0019** | **0.0462** | **0.0002** | 0.3203 | 0.3828 | 0.1875 |
| Day 6 | **<0.0001** | **0.0106** | **0.0001** | **0.0352** | 0.2500 | 0.2500 |
| Day 7 | **<0.0001** | **0.0116** | **<0.0001** | 0.1016 | 0.2344 | 0.2500 |
| Day 8 | **<0.0001** | **0.0046** | **<0.0001** | **0.0234** | 0.1953 | 0.1250 |
| Day 9 | **<0.0001** | **0.0009** | **<0.0001** | **0.0059** | 0.1094 | 0.1250 |
| Day 10 | **<0.0001** | **0.0001** | **<0.0001** | **0.0098** | 0.1172 | 0.1250 |
| Day 11 | **<0.0001** | **0.0002** | **<0.0001** | **0.0195** | 0.0938 | 0.1250 |